Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC

In this video, Shirish M. Gadgeel, MD, of  Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.

Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Shirish M. Gadgeel, MD Source Type: news